Investing.com -- There is a higher potential for downside than upside in Biogen Inc's (NASDAQ:BIIB) shares, UBS analysts said Thursday, lowering their price target on the stock from $234 to $202.
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now?
For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...